衣原体(C.)沙眼,全球性传播感染(STIs)的主要原因,仍然是一个重大的公共卫生问题。大多数感染是无症状的,如果不及时治疗,严重的后遗症,如不孕和慢性盆腔疼痛可发生。尽管经过几十年的研究,有效的疫苗仍然难以捉摸。这篇综述集中于主要外膜蛋白(MOMP)衍生的构建体作为沙眼衣原体疫苗接种的有希望的候选物的潜力。MOMP,沙眼衣原体外膜中最丰富的蛋白质,由于其抗原特性,多年来一直是疫苗研究的焦点。为了克服与使用全MOMP作为疫苗抗原相关的问题,衍生结构已被研究。由于这些构建体通常没有足够的免疫原性,需要抗原递送系统或伴随的佐剂。此外,已经用这些MOMP衍生的疫苗抗原探索了几种免疫途径,确定最佳路线仍然是一个正在进行的研究领域。讨论了沙眼衣原体疫苗接种领域的未来方向和挑战。
Chlamydia (C.) trachomatis, a leading cause of sexually transmitted infections (STIs) worldwide, continues to be a significant public health concern. The majority of infections are asymptomatic and, when left untreated, severe sequelae such as infertility and chronic pelvic pain can occur. Despite decades of research, an effective vaccine remains elusive. This review focuses on the potential of Major Outer Membrane Protein (
MOMP)-derived constructs as promising candidates for C. trachomatis vaccination.
MOMP, the most abundant protein in the outer membrane of C. trachomatis, has been a focal point of vaccine research over the years due to its antigenic properties. To overcome issues associated with the use of full
MOMP as a vaccine antigen, derivative constructs have been studied. As these constructs are often not sufficiently immunogenic, antigen delivery systems or accompanying adjuvants are required. Additionally, several immunization routes have been explored with these
MOMP-derived vaccine antigens, and determining the optimal route remains an ongoing area of research. Future directions and challenges in the field of C. trachomatis vaccination are discussed.